Group 1 - The stock of Axogen (NASDAQ: AXGN) has increased by 204% over the past 12 months due to several catalysts impacting its stock price [1] Group 2 - The article does not provide additional information on the industry or other companies, focusing solely on Axogen's performance [1]

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is AxoGen (AXGN) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.AxoGen is one of 1020 companies in the Medical group. The Medical group currently sits at #3 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the avera ...

AxoGen (AXGN) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.The power of a chan ...

AxoGen (AXGN) closed the last trading session at $13.34, gaining 0.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $17.50 indicates a 31.2% upside potential.The average comprises six short-term price targets ranging from a low of $15 to a high of $20, with a standard deviation of $1.64. While the lowest estimate indicates an increase of 12.4% from the current price level, the mo ...

Axogen, Inc (NASDAQ:AXGN) Q3 2024 Results Conference Call November 7, 2024 8:00 AM ET Company Participants Michael Dale - Chairman and Chief Executive Officer Nir Naor - Chief Financial Officer Conference Call Participants Chris Pasquale - Nephron Research Michael Sarcone - Jefferies Caitlin Cronin - Canaccord Genuity Mike Kratky - Leerink Partners Jayson Bedford - Raymond James Ross Osborn - Cantor Fitzgerald Dave Turkaly - Citizens JMP Operator Good morning, everyone. Joining me on today's call is Michael ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Non-accelerated filer ☐ Smaller reporting company ☐ Emerging growth company ☐ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to______________ Commission file number: 001-36046 Axogen, Inc. ...

Axogen, Inc Reports Third Quarter 2024 Financial Results and Provides BLA Update ALACHUA and TAMPA, FL – November 7, 2024 – Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the third quarter ended September 30, 2024. Third Quarter Financial Results • Third quarter revenue was $48.6 million, a 17.9% increase compared to the third quarter of 2023. • In the third qua ...

AxoGen (AXGN) shares soared 8.2% in the last trading session to close at $14.71. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 0.2% gain over the past four weeks.Axogen scored a strong price increase driven by bullish market sentiment surrounding Fed minutes released on Wednesday. For investors' note Fed made an aggressive 50-bps rate cut on Sept.18 which is expected to boost the investment and research scenario within the MedT ...

September has always been the worst month for the stock market. In early September, stocks gyrated as investors were concerned about a cooling U.S. economy. However, things have begun to improve following the Federal Reserve’s half-point interest rate cut that restored faith in economic strength. According to the Dow Jones Market Data, the S&P 500, the Dow and the Nasdaq have gained more than 1% this month and are about to crush their dismal September run for the first time in five years. And since stocks a ...

ALACHUA, Fla. and TAMPA, Fla., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced that it has completed the rolling submission process for its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Avance Nerve Graft®. “I am proud of the significant progress our team has made towards the regulatory transition of Avance from a tissue to a biologic,” s ...